The Patients’ Experience After Stem Cell Transplant

Overview

This study will examine how adults ≥ 60 years old thinking and memory abilities are affected by stem cell transplant; whether these changes affect day-to-day activities and quality of life and how thinking and memory abilities are affected by genetics, depression, anxiety and physical function. Genetics and other factors may affect the brain's chemicals or structure, and may increase risk for negative effects on thinking and memory.

Full Title of Study: “Measuring Cognition, Physical Function, and Quality of Life After Hematopoietic Cell Transplantation in Adults >/= 60 Years: A Feasibility Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 11, 2022

Detailed Description

In this study, the investigators are looking to understand: 1) how adults ≥ 60 years old thinking and memory abilities are affected by stem cell transplant; 2) whether these changes affect day-to-day activities and quality of life; and 3) how thinking and memory abilities are affected by genetics, depression, anxiety and physical function. Genetics and other factors may affect the brain's chemicals or structure, and may increase risk for negative effects on thinking and memory. Participants will undergo neurocognitive testing along with the collection of a saliva sample and completing a battery of questionnaires and assessments.

Clinical Trial Outcome Measures

Primary Measures

  • Assess differences with cognitive function in older patients undergoing allogeneic or autologous stem cell transplant at 4 timepoints.
    • Time Frame: Before transplant; Post Transplant at 100 days, 6 months, and 12 months
    • Cognition will be measured using a neuropsychological battery.

Secondary Measures

  • Assess quality of life of of older patients undergoing allogeneic and autologous transplant at 4 timepoints.
    • Time Frame: Before transplant; Post Transplant at 100 days, 6 months, and 12 months
    • Quality of life will be measured with the EORTC Quality of Life-30C questionnaire.
  • Assess activity engagement of older patients undergoing allogeneic and autologous transplant at 4 timepoints.
    • Time Frame: Before transplant; Post Transplant at 100 days, 6 months, and 12 months
    • Activity engagement will be measured with the Activity Card Sort-modified.
  • Describe genetic variations in genes potentially involved in cognitive function and cancer treatment.
    • Time Frame: 1 time collection: Before transplant
    • A saliva sample will be collected to look at genetic variations.

Participating in This Clinical Trial

Inclusion Criteria

1. Between the ages of 60-85 2. Diagnosed with a hematological malignancy 3. Is considering an autologous or allogeneic stem cell transplant OR has undergone stem cell transplant in the past 12 months and seen by the PI for pre-transplant evaluation. 4. Is able to read, write, speak, and understand English Exclusion Criteria:

1. As per self report or medical record, history of central nervous system involvement and/or history of cranial irradiation or intrathecal chemotherapy except for patients with history of prophylactic intrathecal chemotherapy. 2. As per self report or medical record, history of stroke, head injury, neurosurgery, seizure disorder, or demyelinating disorder. 3. As per self report or medical record, history of substance use disorder. 4. As per self report or in the judgement of the consenting professional, uncorrected vision loss. 5. As per self report or medical record, primary psychiatric disorder necessitating inpatient treatment in the last 12 months. 6. As per self report or medical record, history of allogeneic and or autologous stem cell transplant.

Gender Eligibility: All

Minimum Age: 60 Years

Maximum Age: 85 Years

Investigator Details

  • Lead Sponsor
    • University of Nebraska
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Thuy Koll, MD, Principal Investigator, University of Nebraska

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.